Browse All

Current Filters

CLEAR FILTER x

TITLE

NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial

Author:Harris, Sarah   Vermersch, Patrick   Montalban, Xavier   Hartung, Hans-Peter   Kappos, Ludwig   Southworth, Harry   Sheffield, James K.   Silva, Diego   Cohen, Jeffrey A.   

Session Name:P1: MS Biomarkers  

Topic:MS and Inflammatory Disease  

Program Number:P1.012  

Author Institution:Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Univ. Lille, Inserm UMR U1172, CHU Lille, FHU Precise, Lille, France, Lille, France  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany  Brain and Mind Centre, University of Sydney, Sydney, Australia  Department of Neurology, Medical University of Vienna, Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Olomouc, Czech Republic  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  Data Clarity Consulting Ltd, Stockport, England, United Kingdom, England, United Kingdom  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH  

Serologic Response and Clinical Outcomes of SARS-CoV-2 Infection and Vaccination in Ozanimod-Treated Participants With Relapsing Multiple Sclerosis

Author:Cree, Bruce A. C.   Maddux, Rachel   Bar-Or, Amit   Hartung, Hans-Peter   Kaur, Amandeep   Brown, Elizabeth   Hu, Sarah   Sheffield, James   Silva, Diego   Harris, Sarah   

Session Name:P2: MS Immunology and Basic Science  

Topic:MS and Inflammatory Disease  

Program Number:P2.018  

Author Institution:Weill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, San Francisco, CA  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, Philadelphia, PA  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany  Brain and Mind Centre, University of Sydney, Sydney, Australia  Department of Neurology, Medical University of Vienna, Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Dusseldorf, Germany  Bristol Myers Squibb, Princeton, New Jersey, San Diego, CA